



In the past 4 years, more than 2/3 of DRDs reviewed by both CDA-AMC and INESSS had aligned evaluation results

Percentage of DRD Files Receiving Positive CDA-AMC Recommendation (2022-2025)



Percentage of DRD Files Receiving Positive INESSS Recommendation (2022-2025)



Number of DRD Files receiving aligned evaluations from CDA-AMC and INESSS (2022-2025 based on CDA-AMC recommendation year)



Data Sources:

- [CDA-AMC Reimbursement Reviews](#); [Orphanet](#) : [Search for an orphan drug](#); [INESSS: Drug products undergoing evaluation and evaluated](#).
- CRAFT 2026 DRD Sub-Report, MORSE Consulting, 2026; MORSE Consulting Data Intelligence Tool.

Note:

- Data accurate as of April 17, 2026.
- This analysis is based on the methodology used for MORSE's CRAFT DRD Sub-report; MORSE defined a DRD as a Non-Oncology file with an indication reviewed by CDA-AMC designated as "orphan" either by the European Medicines Agency (EMA) or the United States Food and Drug Administration (FDA) per the Orphanet portal; oncology and blood products are not included.
- An INESSS recommendation is considered "positive" if the therapeutic value is recognized.
- Aligned recommendations include files receiving positive recommendations from both CDA-AMC and INESSS and files receiving negative recommendations from both CDA-AMC and INESSS.

